Lipidomic signatures of colonic inflammatory bowel diseases: a pilot study

Tefas, Cristian; Socaciu, Carmen; Moraru, Corina; Tanţău, Marcel

doi:10.15403/jgld-188

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetracosanoic acid, phosphatidylcholine (PC), lysophosphatidylcholine (LPC), sphingomyelin (SM), and diacylglycerol were significantly lower in patients with colonic IBD than in healthy controls, as previously reported [15].…”

Section: Lipid Profiling Of Colonic Ibdssupporting

confidence: 78%

“…When comparing IBD patients to healthy subjects, the former have lower PC and LPC levels [15]. The two lipid groups along with PE and lysophosphatidylethanolamines (LPE) are virtually found in the cell membranes of all organisms and play a role in cellular signaling, division, apoptosis, and inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…We previously reported that cholesteryl esters show higher values in patients with colonic IBD than in healthy subjects [15]. These changes could be explained by lipid mobilization or by increased intestinal permeability.…”

Section: Wwwbjbmsorgmentioning

confidence: 91%

See 2 more Smart Citations

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Tefas

Ciobanu

Tanţău

et al. 2019

Bosn J of Basic Med Sci

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are conditions that still pose significant problems. A third of the patients are either misdiagnosed or a proper diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) cannot be made. We need new biomarkers, so that we can offer patients the best treatment and keep the disease in an inactive state for as long as possible. Alterations in metabolic profiles have been incriminated in the pathophysiology of IBD. The aim of the present study was to identify molecules that could serve as biomarkers for a positive diagnosis of IBD as well as to discriminate UC from colonic CD. Twenty-two patients with active colonic IBD (UC = 17, CD = 5) and 24 age- and gender-matched healthy controls were enrolled. Plasma lipid and metabolic profiles were quantified using ultra-high performance liquid chromatography combined with mass spectrometry. Univariate and multivariate statistical tests were employed. Six lipid species and seven metabolites were significantly altered in IBD compared to healthy controls, with the majority belonging to glycerophospholipid, linoleic acid, and sphingolipid metabolisms. Five lipid species and only one metabolite were significantly increased in UC compared to CD. This preliminary study suggests that lipid and metabolic profiling of serum can become diagnostic tools for IBD. In addition, they can be used to differentiate between CD and UC.

show abstract

Section: Lipid Profiling Of Colonic Ibdssupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Tefas

Ciobanu

Tanţău

et al. 2019

Bosn J of Basic Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…Phospholipids are essential for the biosynthesis of lipoproteins. As reported in Table 5 , in patients with IBD, circulating phospholipids were found decreased in various studies ( Bjerrum et al, 2010 , 2017 ; Fan et al, 2015 ; Kolho et al, 2017 ; Scoville et al, 2018 ; Tefas et al, 2019 , 2020 ). Factors, such as the compromised integrity of the intestinal mucosa, TNF-α, NF- k B, mitogen-activated protein kinase (MAPK) pathway, and peroxisome proliferator-activated receptor (PPAR) signaling, seem to be closely implicated in phospholipids depletion.…”

Section: Metabolomics In Ibd and Covid-19mentioning

confidence: 84%

“…Factors, such as the compromised integrity of the intestinal mucosa, TNF-α, NF- k B, mitogen-activated protein kinase (MAPK) pathway, and peroxisome proliferator-activated receptor (PPAR) signaling, seem to be closely implicated in phospholipids depletion. Glycerophosphocholine was significantly decreased in two subsequent studies ( Bjerrum et al, 2010 , 2017 ); more recently, in patients with extensive UC and colonic CD, tetracosanoic acid, phosphatidylcholine, (PC) lysophosphatidylcholine (LPC), sphingomyelin (SM), and diacylglycerol were found decreased compared with healthy controls; interestingly, saturated LPC (18:2) was found decreased whereas polyunsaturated LPC (20:4) and LPC (22:6) increased ( Tefas et al, 2019 , 2020 ). It is likely that the anti-inflammatory polyunsaturated LPC effectively antagonized the pro-inflammatory activity of saturated LPC.…”

Section: Metabolomics In Ibd and Covid-19mentioning

confidence: 94%

Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin

et al. 2022

View full text Add to dashboard Cite

The integrity of the gastrointestinal tract structure and function is seriously compromised by two pathological conditions sharing, at least in part, several pathogenetic mechanisms: inflammatory bowel diseases (IBD) and coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. IBD and COVID-19 are marked by gut inflammation, intestinal barrier breakdown, resulting in mucosal hyperpermeability, gut bacterial overgrowth, and dysbiosis together with perturbations in microbial and human metabolic pathways originating changes in the blood and fecal metabolome. This review compared the most relevant metabolic and microbial alterations reported from the literature in patients with IBD with those in patients with COVID-19. In both diseases, gut dysbiosis is marked by the prevalence of pro-inflammatory bacterial species and the shortfall of anti-inflammatory species; most studies reported the decrease in Firmicutes, with a specific decrease in obligately anaerobic producers short-chain fatty acids (SCFAs), such as Faecalibacterium prausnitzii. In addition, Escherichia coli overgrowth has been observed in IBD and COVID-19, while Akkermansia muciniphila is depleted in IBD and overexpressed in COVID-19. In patients with COVID-19, gut dysbiosis continues after the clearance of the viral RNA from the upper respiratory tract and the resolution of clinical symptoms. Finally, we presented and discussed the impact of gut dysbiosis, inflammation, oxidative stress, and increased energy demand on metabolic pathways involving key metabolites, such as tryptophan, phenylalanine, histidine, glutamine, succinate, citrate, and lipids.

show abstract

Biomarkers of Metabolomics in Inflammatory Bowel Disease and Damp-Heat Syndrome: A Preliminary Study

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Aims. This study aims to investigate the potential biomarkers of inflammatory bowel disease (IBD) and IBD with damp-heat syndrome (IBD-DH) by metabolomics. Methods. Plasma and urine samples were collected from 15 healthy controls and 30 IBD patients, including 15 IBD-DH and 15 IBD with spleen deficiency syndrome (IBD-SD), which was coded as SF8G and SF70 according to the International Classification of Diseases Eleventh Revision (ICD-11) issued by World Health Organization. Pseudotargeted metabolomics method was used based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry and triple-quadrupole mass spectrometry. Results. Under the condition of false discovery rate (FDR) < 0.05, variable importance projection (VIP) > 1.0, and fold change (FC) > 1.5 or < 2/3, we found 57 plasma differential metabolites and 20 urinary differential metabolites in IBD. Then, with area under the curve (AUC) ≥ 0.85 and FC ≥ 2 or ≤ 0.3, 11 potential biomarkers were identified, such as acylcarnitine (ACar 20:4, ACar 18:1, and ACar 20:3), 3-indoleacetic acid, hippuric acid, and dehydroepiandrosterone sulfate, which is related to intestinal microbiota and immune response. However, less obvious differences were observed in IBD-DH when compared with IBD-SD. Under the condition of FDR < 0.2, VIP >1.0, and FC > 1.5 or < 2/3, we identified 16 plasma differential metabolites. In urine samples, IBD-DH and IBD-SD had the same metabolite pattern. With AUC ≥ 0.80, 7 differential plasma metabolites, mainly glycerophospholipids, were identified in IBD-DH. Kyoto Encyclopedia of Genes and Genomes analysis indicated that metabolic pathways, such as citrate cycle and amino acids metabolism, were mainly responsible for the distinction between IBD and healthy controls, whereas glycerophospholipid metabolism perturbation was not only a manifestation of IBD but also an important pathway to distinguish two subtypes defined by traditional medicine, IBD-DH and IBD-SD. Conclusion. In this study, we found that several metabolites of aromatic acids and lipid derivatives could act as potential biomarkers to discriminate IBD from healthy controls. Glycerophospholipids metabolites might be used to differentiate IBD-DH from IBD-SD.

show abstract

Lipidomic signatures of colonic inflammatory bowel diseases: a pilot study

Abstract: .

Cited by 4 publications

References 6 publications

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

The potential of metabolic and lipid profiling in inflammatory bowel diseases: a pilot study

Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin

Biomarkers of Metabolomics in Inflammatory Bowel Disease and Damp-Heat Syndrome: A Preliminary Study

Contact Info

Product

Resources

About